Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs [Yahoo! Finance]
Ginkgo Bioworks Holdings, Inc. (DNA)
Company Research
Source: Yahoo! Finance
biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor (CAR) and switch receptor libraries. Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases. In contrast to legacy cell therapy design, the company uses a combinatorial approach to build and screen cell therapy components that work in concert with one another to yield novel cell behaviors. Modulus has used its platform to develop and screen libraries of novel NK-specific and T-cell specific CAR and switch receptor designs, which enable improved control and performance of immune cell-based therapies. This technology has the potential to improve the safety and efficacy of cell therapies by allowing for more precise control over activation and targeting. Modulus' CAR-NK and CAR-T components are designed to enhance proliferation and cytotoxicity, even in inhospitable cellular
Show less
Read more
Impact Snapshot
Event Time:
DNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNA alerts
High impacting Ginkgo Bioworks Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
DNA
News
- Global Synthetic Biology Market Research 2024-2035: The Bioeconomy's Transformation - An Industry on the Brink of Revolution with profiles of 295+ Companies [Yahoo! Finance]Yahoo! Finance
- THNQ: AI Not As Hot A Sector As You May Think [Seeking Alpha]Seeking Alpha
- TetraScience Partners with Google Cloud to Catalyze Scientific AI Innovation [Yahoo! Finance]Yahoo! Finance
- Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products [Yahoo! Finance]Yahoo! Finance
- Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery ProductsPR Newswire
DNA
Earnings
- 2/29/24 - Miss
DNA
Sec Filings
- 4/29/24 - Form 144
- 4/26/24 - Form 144
- 4/25/24 - Form 144
- DNA's page on the SEC website